NASDAQ:COLL - Collegium Pharmaceutical Stock Price, Forecast & News

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical Inc (NASDAQ:COLL) issued its quarterly earnings data on Wednesday, November, 6th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.03. The specialty pharmaceutical company had revenue of $72.94 million for the quarter, compared to the consensus estimate of $74.32 million. Collegium Pharmaceutical had a negative net margin of 3.86% and a negative return on equity of 13.14%. The firm's revenue was up 3.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.50) earnings per share. View Collegium Pharmaceutical's Earnings History.

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Collegium Pharmaceutical.

Collegium Pharmaceutical will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Collegium Pharmaceutical issued an update on its FY 2020 Pre-Market earnings guidance on Friday, February, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $320-340 million, compared to the consensus revenue estimate of $331.36 million.

8 Wall Street analysts have issued 12-month price objectives for Collegium Pharmaceutical's shares. Their forecasts range from $22.00 to $43.00. On average, they anticipate Collegium Pharmaceutical's stock price to reach $32.29 in the next twelve months. This suggests a possible upside of 35.1% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.

Media stories about COLL stock have trended negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Collegium Pharmaceutical earned a coverage optimism score of -2.5 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Collegium Pharmaceutical.

Collegium Pharmaceutical saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,310,000 shares, an increase of 13.2% from the January 15th total of 2,040,000 shares. Based on an average daily trading volume, of 451,400 shares, the days-to-cover ratio is currently 5.1 days. Currently, 7.9% of the company's stock are sold short. View Collegium Pharmaceutical's Current Options Chain.

Some companies that are related to Collegium Pharmaceutical include Genmab A/S (GMAB), Allakos (ALLK), Apellis Pharmaceuticals (APLS), ChemoCentryx (CCXI), Taro Pharmaceutical Industries (TARO), Deciphera Pharmaceuticals (DCPH), Alkermes (ALKS), Amicus Therapeutics (FOLD), Uniqure (QURE), Insmed (INSM), Arena Pharmaceuticals (ARNA), Biohaven Pharmaceutical (BHVN), ArQule (ARQL), Karuna Therapeutics (KRTX) and Epizyme (EPZM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), AbbVie (ABBV), NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Bausch Health Companies (BHC), Celgene (CELG), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT) and Ocular Therapeutix (OCUL).

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (13.43%), Franklin Resources Inc. (5.28%), Renaissance Technologies LLC (3.74%), Rice Hall James & Associates LLC (3.15%), Emerald Advisers LLC (2.33%) and Emerald Mutual Fund Advisers Trust (2.28%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan, Paul Brannelly and Scott Dreyer. View Institutional Ownership Trends for Collegium Pharmaceutical.

COLL stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Sectoral Asset Management Inc, Massachusetts Financial Services Co. MA, Franklin Resources Inc., Charles Schwab Investment Management Inc., Oxford Asset Management LLP, J. Goldman & Co LP and Bank of America Corp DE. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan and Scott Dreyer. View Insider Buying and Selling for Collegium Pharmaceutical.

COLL stock was bought by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Renaissance Technologies LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, Driehaus Capital Management LLC, Janus Henderson Group PLC and Bank of Montreal Can. View Insider Buying and Selling for Collegium Pharmaceutical.

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of COLL stock can currently be purchased for approximately $23.89.

Collegium Pharmaceutical has a market capitalization of $801.03 million and generates $280.41 million in revenue each year. The specialty pharmaceutical company earns $-39,130,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.View Additional Information About Collegium Pharmaceutical.

The official website for Collegium Pharmaceutical is http://www.collegiumpharma.com/.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.